---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-102874"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:23:40.369614+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte reports positive Phase 2 data for VAX-24 in adults 65+; met key immunogenicity criteria vs Prevnar 20

## Summary
- VAX-24 2.2mcg dose met OPA non-inferiority for 18 of 20 serotypes common with Prevnar 20 and superiority for all four unique serotypes.
- Robust immune responses across all 24 serotypes at all doses in adults 65+, confirming prior Phase 2 results in adults 50-64.
- Full six-month safety data from both adult studies showed VAX-24 safety and tolerability similar to PCV20 with no related serious adverse events.
- Prespecified pooled analyses (age 50+ and 60+) showed VAX-24 2.2mcg met OPA non-inferiority for all 20 common serotypes and superiority for four unique.
- Company plans End-of-Phase 2 meeting with FDA in H2 2023; topline Phase 3 data in adults expected in 2025.

## SEC filing metadata
- accession: 0001193125-23-102874
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312523102874/0001193125-23-102874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312523102874/d492750d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-102874
- JSON: https://secwatch.observer/filing/0001193125-23-102874.json
- Plain text: https://secwatch.observer/filing/0001193125-23-102874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.